Lapatinib with whole brain radiotherapy in patients with brain metastases from breast and non-small cell lung cancer: a phase II study of the Hellenic Cooperative Oncology Group (HeCOG)

Small molecules, mainly tyrosine kinase inhibitors, are currently used in various malignancies. Lapatinib, a dual inhibitor of EGFR/HER2 tyrosine kinases, has demonstrated effectiveness in brain metastases from HER2-overexpressing breast cancer. It also appears to sensitize EGFR-expressing cell line...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neuro-oncology Vol. 134; no. 2; pp. 443 - 451
Main Authors:	Christodoulou, Christos, Kalogera-Fountzila, Anna, Karavasilis, Vasilios, Kouvatseas, George, Papandreou, Christos N., Samantas, Epaminontas, Varaki, Kalliopi, Papadopoulos, Georgios, Bobos, Mattheos, Rallis, Grigorios, Razis, Evangelia, Goudopoulou, Athina, Kalogeras, Konstantine T., Syrigos, Konstantinos N., Fountzilas, George
Format:	Journal Article
Language:	English
Published:	New York Springer US 01-09-2017 Springer Nature B.V
Subjects:	Brain cancer Breast cancer Clinical Study Clinical trials Dexamethasone Epidermal growth factor receptors ErbB-2 protein Lung cancer Magnetic resonance imaging Medicine Medicine & Public Health Metastases Metastasis Neurology Non-small cell lung carcinoma Oncology Protein-tyrosine kinase Radiation therapy Targeted cancer therapy Toxicity Brain metastases Breast cancer Lapatinib Whole brain radiotherapy Non-small cell lung cancer
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!